Glaukos Corporation (GKOS)
Automate Your Wheel Strategy on GKOS
With Tiblio's Option Bot, you can configure your own wheel strategy including GKOS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GKOS
- Rev/Share 7.1424
- Book/Share 13.4887
- PB 7.0333
- Debt/Equity 0.1381
- CurrentRatio 6.4869
- ROIC -0.1137
- MktCap 5420919235.0
- FreeCF/Share -0.94
- PFCF -101.8223
- PE -43.444
- Debt/Assets 0.1092
- DivYield 0
- ROE -0.1727
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | GKOS | Wells Fargo | Overweight | Equal Weight | -- | $86 | May 1, 2025 |
| Upgrade | GKOS | Mizuho | Neutral | Outperform | $140 | $200 | Feb. 19, 2025 |
| Upgrade | GKOS | Citigroup | Neutral | Buy | $132 | $162 | Dec. 11, 2024 |
| Initiation | GKOS | UBS | -- | Buy | -- | $182 | Dec. 6, 2024 |
News
Here's Why You Should Retain Glaukos Stock in Your Portfolio
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Positive
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.
Read More
Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Glaukos (GKOS) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
GKOS Stock Falls Despite Q1 Earnings & Revenue Beat, Margins Decline
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Negative
Glaukos' first-quarter results showcase a strong uptick in revenues. However, continued operating loss remains a cause of concern.
Read More
Glaukos Corporation (GKOS) Q1 2025 Earnings Call Transcript
Published: April 30, 2025 by: Seeking Alpha
Sentiment: Neutral
Glaukos Corporation (NYSE:GKOS ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Chris Lewis - Vice President of Investor Relations and Corporate Affairs Tom Burns - Chairman and CEO Joe Gilliam - President and COO Alex Thurman - CFO Conference Call Participants Tom Stephan - Stifel Ryan Zimmerman - BTIG Larry Biegelsen - Wells Fargo Allen Gong - J.P. Morgan David Saxon - Needham Adam Maeder - Piper Sandler Joanne Wuensch - Citibank Margaret Andrew - William Blair Richard Newitter - Truist Securities Michael Sarcone - Jefferies Anthony Petrone - Mizzou Group Danielle Antalffy - …
Read More
Baron Health Care Fund Q1 2025 Top Contributors And Detractors
Published: April 29, 2025 by: Seeking Alpha
Sentiment: Positive
Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals saw increased investor confidence in its cystic fibrosis franchise and evolving pipeline, including promising non-opioid pain treatments and kidney disease drugs. UnitedHealth Group's shares gained as 2024 headwinds subsided, Medicare Advantage rates improved, and higher-margin Optum segments grew, insulating it from tariff impacts.
Read More
Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™
Published: February 24, 2025 by: Business Wire
Sentiment: Neutral
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it has received the “Day 74” notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for Epioxa™ (Epi-on), its next-generation corneal cross-linking iLink therapy for the treatment.
Read More
Glaukos Corporation (GKOS) Q4 2024 Earnings Call Transcript
Published: February 21, 2025 by: Seeking Alpha
Sentiment: Neutral
Glaukos Corporation (NYSE:GKOS ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Chris Lewis - Vice President, Investor Relations and Corporate Affairs Tom Burns - Chairman and Chief Executive Officer Joe Gilliam - President and Chief Operating Officer Conference Call Participants Tom Stephen - Stifel Richard Newitter - Truist Securities Allen Gong - JPMorgan Michael Sarcone - Jefferies Mason Carrico - Stephens Anthony Petrone - Mizuho Danielle Antalffy - UBS Operator Welcome to Glaukos Corporation's Fourth Quarter and Full-Year 2024 Financial Results Conference Call. Copies of the company's press release and quarterly summary document, both …
Read More
About Glaukos Corporation (GKOS)
- IPO Date 2015-06-25
- Website https://www.glaukos.com
- Industry Medical - Devices
- CEO Mr. Thomas William Burns
- Employees 995